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Gene-markerGene ranking is an important problem in bioinformatics. Here, we propose a new framework for ranking
biomolecules (viz., miRNAs, transcription-factors/TFs and genes) in a multi-informative uterine leiomy-
oma dataset having both gene expression and methylation data using (statistical) eigenvector centrality
based approach. At first, genes that are both differentially expressed and methylated, are identified using
Limma statistical test. A network, comprising these genes, corresponding TFs from TRANSFAC and ITFP
databases, and targeter miRNAs from miRWalk database, is then built. The biomolecules are then ranked
based on eigenvector centrality. Our proposed method provides better average accuracy in hub gene and
non-hub gene classifications than other methods. Furthermore, pre-ranked Gene set enrichment analysis
is applied on the pathway database as well as GO-term databases of Molecular Signatures Database with
providing a pre-ranked gene-list based on different centrality values for comparing among the ranking
methods. Finally, top novel potential gene-markers for the uterine leiomyoma are provided.
 2015 Elsevier Inc. All rights reserved.1. Introduction
DNA methylation is an important epigenetic factor
[36,38,40,42,52] that refers to the addition of a methyl group
(-CH3) to position 5 of the cytosine pyrimidine ring (by DNA
methyltransferase or DNMT enzymes) or the number 6 nitrogen
of the adenine purine ring in genomic DNA. It modifies, in general
decreases, the expression levels of genes. In human DNA,
approximately 80–90% of CpG sites (or CG sites) are found to be
methylated throughout the entire genome. But, an exception of it
is found in CpG islands (i.e., the stretches whose length is near
about 1 kilobase, the C and G contents are greater than or equal
to 55%, and CpG ratio is greater than 0.65) where these sequences
are identified as hypo-methylated or unmethylated. The methyla-
tion of these CpG islands can make inappropriate gene silencing (e.
g., transcriptional repression, the silencing of tumor suppressor
genes or TSGs in cancer cells). In normal cells, peri-centromeric
heterochromatin is hyper-methylated; but in tumor cells, the hete-
rochromatin becomes hypo-methylated [41,53]. Thereby, it creates
genomic instability. In tumorigenesis, the two alternations (i.e.,
transcriptional repression and genomic instability) in methylation
are important events (see [33,34]). It is noted that current studyabout methylation reveals that either (i) DNA methylation is a con-
sequence of gene regulation, or (ii) it controls gene expression
changes; i.e., DNA methylation performs either a passive role in
gene regulation or an active role in gene regulation [5,6]. Thus,
the actual relationship between DNA methylation and gene
expression is still unknown [5–7]. This becomes a latest topic of
debate.
Beadchip is an efficient technique for generating genome-wide
DNA methylation [1,5,13,24,35] profiling in infinium II platform.
Besides that, microarray technique is a useful tool for measuring
gene expression data [18–20,22,23,28] across different experimen-
tal and control samples. Furthermore, both the expression [31,32]
and methylation data matrix are organized in such a way that rows
and columns indicate genes and samples, respectively.
A transcription factor (TF) [30] is basically a protein which
binds to specific DNA sequences. It maintains the flow of genetic
information alone or with other proteins in a complex from DNA
to messenger RNA by promoting, or blocking the hiring of RNA
polymerase to specific genes. TFs have a significant role in affecting
the gene expression as well as methylation levels.
Uterine tumor or leiomyoma is a common benign (i.e., non-
cancerous) tumor of the female muscular wall of the uterus
[13,24,57,58]. It often causes heavy pain and bleeding. The female
hormone (i.e., estrogen) increases the size of the leiomyoma. But,
after menopause, it becomes under control. Leiomyomas can be
located in various parts of the uterus. Three types of uterine tumors
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formed. During pregnancy, the size of the tumor can automatically
increase. At the age of reproduction, it becomes symptomatic for
30% of all women and up to 70% of African–American women. Iden-
tifying the biomolecules (gene, microRNAs/miRNAs/miRs, and TFs)
[9,14] which significantly dysregulate in uterine tumor, can provide
important information with great therapeutic value.
In this article, we propose a newmethodology to rank the biomo-
lecules that may be involved in uterine tumor formation by applying
statistical [17,21,25–27] and eigenvector centrality-based [8,46]
approaches from a combined biological data. For this purpose, both
expression and methylation data of normal and experimental/dis-
eased samples are used. First of all, genes that are both differentially
expressed (DE) and differentially methylated (DM), are determined
using apopularnon-parametric statistical test Limma[21]whichper-
formswell for all sample sizes of data (i.e., small/medium/large num-
ber of samples) at any type of data distribution (viz., normal/non-
normal distribution). Thereafter, the genes of (DEdown \ DMhyper),
(DEup \ DMhypo), (DEup \ DMhyper), (DEdown \ DMhypo) genesets are iden-
tified. These four genesets are together called as DEM. Thereafter,
transcription factors (TFs) that have impact on the regulationof genes
belonging to DEM set, are found from TRANSFAC professional data-
base (release 2011.2) [2,29] and ITFP website [29,30]. Subsequently,
miRNAswhich targets the genes belonging to DEM set, are identified
using miRWalk database. A network, comprising the genes, TFs and
miRNAs is then built. The TFs, miRNAs and genes are then ranked
based on eigenvector centrality score [10,16]. Finally, validation
experiments are conducted through KEGG pathways and GENE
ONTOLOGY (GO) ENRICHMENT of the top ranked 25 biomolecules
using David database [54].
For evaluating the effectiveness and superiority of our proposed
biomolecule ranking method over the other existing ranking meth-
ods for the combined biological dataset, we have performed hub
gene and non-hub gene classifications using the proposed ranking
method (through eigenvector centrality values) and other ranking
methods (through other centrality values), individually. Further-
more, for comparing the proposed ranking method with the other
rankingmethods, we have utilized pre-ranked Gene set enrichment
analysis (pre-ranked GSEA) tool [51] on the pathway database (viz.,
‘‘c2.cp.kegg.v4.0.symbols.gmt”) as well as GO-term databases (viz.,
‘‘c5.bp.v4.0.symbols.gmt”, ‘‘c5.cc.v4.0.symbols.gmt” and ‘‘c5.mf.v4.
0.symbols.gmt”) of Molecular Signatures Database (MSigDB) with
providing a pre-ranked list of genes prepared by different centrality
values. Notably, we perform the above mentioned analysis for
(DEdown \ DMhyper) and (DEup \ DMhypo) genesets, individually.
Different centrality measures have been applied on gene regula-
tory network (GRN) to find top central genes [3,4,15,16]. However,
an integrated analysis of DE and DM has not been attempted in the
literature, although it is expected that using methylation data we
can provide improved results as it is an important epigenetic
factor.
The rest of the article is ordered as follows. Section 2 represents
literature review as well as proposed method. Section 3 describes
the source and other description of the real-life combined dataset,
as well as the experimental results and discussion. Finally, Section 4
draws the conclusion of our article.
2. Material and methods
In this section, we are going to discuss the literature review and
the proposed methodology, consecutively.
2.1. Literature review
Centrality analysis is a method of ranking of the nodes (vertices)
in network for identifying interesting nodes of the network [15]. Inother words, centrality analysis is effective for determining the key
biomolecules (central nodes) which control the biological pro-
cesses. It helps to find the controller nodes of the whole biological
network [37,39]. There are different types of network centrality
measures that are useful in different prospectives. Among them,
degree centrality (DC) [12,16] is simplest one.
In DC measure, only the degree of a node is taken into account
where degree of the node denotes the number of nodes which are
directly connected to it (i.e., (nearest neighbors of the node)). In DC
measure, each neighbor of the node is treated as equally important
for determining centrality of the node. But, there are many real life
situations (for e.g., different genes/miRNAs/TFs) where all the rela-
tionships between the nodes in a network are not equally impor-
tant. In that case, a node in the network is more central when it
connects to many influential (high-scoring/central) nodes. This
type of centrality is stated as eigenvector centrality (i.e., EC) mea-
sure. In other words, EC is a measure of a node’s influence in a net-
work. It accounts for the notion that the connections to influential
(high-scoring/central) nodes are more significant than the connec-
tions to low-scoring nodes.
Another popular network centrality measure is closeness cen-
trality (CC) [12,16]. The CC value of a node (say, a) is defined as
the reciprocal of the summation of minimum distances (i.e., length
of shortest path) of the node to all other nodes of the network. In
other words, CCðaÞ ¼ 1=ðPðb2N;b–aÞshortdistða; bÞÞ, where N denotes
the set of all nodes in the network. Wuchty and Stadler [72] uti-
lized CC measure in different biological networks, and represent
the relationship with the problem of service facility location.
Besides this, betweenness centrality (BC) [11,16] is another impor-
tant centrality measure. The BC value of a node is defined as the
ratio of the summation of the number of shortest paths between
node-pairs which pass through the node to the total number of
shortest paths between node-pairs. This centrality measure is use-
ful for identifying the principal node which acts the role of a bridge
between node-pairs in the network. Furthermore, there are differ-
ent centrality measures (viz., clustering coefficient based centrality
[10,44], weighted clustering coefficient based centrality [45], k-
coreness centrality [49], subgraph centrality [47] measures, etc.)
that are applied in different types of network for different reasons.
In case of clustering coefficient based centrality, clustering coeffi-
cient is calculated depending upon local clustering and triangle
motifs count. According to Watts and Strogatz [43], a local value,
Cj = (number of triangles that are connected to j)/(number of tri-
ples that are centered on j). In case of the nodes having degree
either 1 or 0, for which both denominator and numerator are 0,
the value of Ci is taken as 0.
The k-core refers to the largest sub-graph of which the nodes
having degree at least k are only existed. If a node is existed in
the k-core but not in the ðkþ 1Þ core, then the coreness of the node
will be k. Therefore, the coreness centrality of the node becomes k.
The k-coreness measure [49] is useful for identifying influential
spreaders in networks. Besides these, the subgraph centrality of a
node is stated as a weighted summation of closed-walks of differ-
ent lengths in the network that are starting and ending at the node
[47].
In this article, we propose a new methodology for ranking bio-
molecules involved in uterine tumor using statistical and Eigenvec-
tor centrality (EC) approaches in miRNA-TF-gene network based on
symmetric relationships for a combined biological data sources
(viz., gene expression and methylation data).
2.2. Proposed approach
In this article, we propose a new methodology for ranking bio-
molecules involved in uterine tumor for combined biological data
by utilizing statistical and centrality based approaches. For this
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eased samples are utilized. We provide a flow-chart of the pro-
posed methodology in Fig. 1.
The steps of our proposed approach are described in the
followings:
2.2.1. Statistical analysis
For microarray/beadchip data, it is necessary to utilize a pre-
filtering analysis (i.e., removal of genes having low variance). If a
gene has very low variance, the corresponding p-value of the gene
becomes very low. Now, if the p-value of the gene is less than a
user-defined threshold, the gene looks like p-value significant;
but actually it may not be significant. Therefore, overall variance
of the data corresponding to each gene is verified, and thereby
the genes having too low variance from both expression and
methylation datasets are eliminated. Notably, in order to find the
cutoff (say, r%) for the pre-filtering, firstly we have ordered the
variances of the genes in ascending order, and then plotted these
in a single graph; and finally identified what percentage of the
genes from ascending order that are very close to each other. This
percentage is chosen as the pre-filtering cutoff (i.e., r%).
The genes that have both expression data as well as methyla-
tion data, are then identified. Thereafter, zero-mean normalization
is applied on the expression data as well as the methylation data to
bring the data into a common scale. The zero-mean normalization
is formulated as:Fig. 1. Flowchart of the prynormi ¼
yi  l
r
; ð1Þ
where 1 6 i 6 #samplesize. Here, l and r denote mean and stan-
dard deviation, respectively of the expression/methylation data of
a gene before normalization. yi and ynormi denote the data-values
at i-th sample of the data before normalization and after normaliza-
tion, respectively.
Now, for identification of up-regulated genes and down-
regulated genes from the expression data, we have utilized a
well-known statistical test, Limma [21] that performs well for both
normal and non-normal distributions for all sample sizes of data
(viz., low/medium/large sample sizes). Similarly, we have applied
the Limma test to obtain hyper-methylated genes and
hypo-methylated genes from the methylation data. The moderated
t-stat in Limma can be demonstrated as:
~tg ¼ b^gﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
ma
þ 1mb
q 
 ð~sgÞ
; ð2Þ
where b^g refers to contrast estimator for the gene g, and ~s2g denotes
posterior sample variance for the g. Here, the size of the samples is
m where m ¼ ma þmb. By the way, the statistic for computing the
contrast estimator for the g is described as follows:
b^g jr2g  Nðbg ;r2gÞ; ð3Þoposed methodology.
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posterior sample variance for the g, the statistic is given below:
~s2g ¼
d0s20 þ dgs2g
d0 þ dg ; ð4Þ
where d0 represents the prior degrees of freedom, and s20 denotes
prior variance of a gene gwhereas dg refers to experimental degrees
of freedom, and s2g denotes the experimental sample variance of the
gene g. Here, d0 < 1, and dg > 0.
Let us assume that set of up-regulated genes, set of down-
regulated genes, set of non-differentially expressed genes, set of
hyper-methylated genes, set of hypo-methylated genes, and set
of non-differentially methylated genes are denoted by
DEup;DEdown;DEnon;DMhyper;DMhypo and DMnon, respectively. In this
regard, for the combined dataset, we identify eight different types
of gene-sets, viz., (a) (DEup \ DMnon), (b) (DEup \ DMhyper), (c)
(DEnon \ DMhyper), (d) (DEdown \ DMhyper), (e) (DEdown \ DMnon), (f)
(DEdown \ DMhypo), (g) (DEnon \ DMhypo), and (h) (DEup \ DMhypo). As
our analysis concerns about both expression and methylation
status of the genes, thus we choose only those genes that are both
differentially expressed and differentially methylated. Thus, we
select only the gene-sets denoted by (b), (d), (f) and (h) for our
experiment as the four gene-sets contain the genes having both
differentially expressed and differentially methylated. Thereafter,
we consider the relationship between DNA methylation and gene
expression. DNA methylation generally decreases the gene
expression levels. But, as stated in Introduction that the actual
relationship between DNA methylation and gene expression is still
unknown [5–7], therefore we have initially considered the four
gene-sets (viz., the gene-sets denoted by (b), (d), (f) and (h))
together for our experiment. Let us assume that the union of the
four gene-sets is denoted by DEM (i.e., differentially expressed
and methylated genes). Therefore, DEM is formulated as follows:
DEM ¼ ððDEup \ DMhypoÞ [ ðDEup \ DMhyperÞ [ ðDEdown
\ DMhypoÞ [ ðDEdown \ DMhyperÞÞ ð5Þ2.2.2. TF-miRNA-gene network analysis
At first, miRNAs which target the obtained genes, are retrieved
from miRWalk database. Subsequently, TFs corresponding to the
genes are also collected from TRANSFAC professional database
(release 2011.2) [29] and ITFP website [29]. Thereafter, a network
is built with the TFs, genes and miRNAs depending upon the con-
nection between the TFs and the genes as well as the connection
between the miRNAs and the (validated) target genes.
In our experiment, we focus on the direct neighbors for measur-
ing the eigenvector centrality score of any vertex. If a vertex is con-
nected to many unimportant nodes, then it might be less
important than a vertex which is connected to a few highly impor-
tant neighbors. For collecting this type of significance, we have uti-
lized eigenvector centrality (i.e., EC) measure on the TF-miRNA-
gene network. Suppose, the direct neighbors of a vertex i are
denoted by the following:
NðiÞ ¼ fq 2 V jði; qÞ 2 E; i– qg; ð6Þ
where V and E refer to set of all vertices and all edges, respectively
in the network. The adjacency matrix of the network (i.e., graph
denoted by G) is given below:
Aði; qÞ ¼ 1; if ði; qÞ 2 E
0; else:

ð7Þ
Here, k denotes the principal (i.e., largest) eigenvalue which is cal-
culated from the following equation:
detðA kIÞ ¼ 0; ð8Þwhere I is identity matrix, and ‘‘det” stands for determinant of
matrix. Thus, the eigenvector (Ev) of all the vertices in the network
is calculated using the following equation:
A Et ¼ k Et: ð9Þ
Now, let us assume that A is a n0  n0 matrix which is written as
follows:
A ¼
a11 a12 . . . a1n0
a21 a22 . . . a2n0
. . . . . . . . . . . .
an01 an02 . . . an0n0
2
6664
3
7775;
where n0 refers to the number of biomolecules (viz., summation of
the identified genes, TFs and miRNAs). In other words, n0 is the
number of nodes in a graph depending on A adjacency matrix.
As the number of biomolecules is n0, thus the eigenvector (Ev)
should be a vector of n0 size. Therefore, Ev matrix can be written
as follows:
Et ¼
et1
et2
. . .
etn0
2
6664
3
7775:
Therefore, Eq. (9) can be written as:
a11 a12 . . . a1n0
a21 a22 . . . a2n0
. . . . . . . . . . . .
an01 an02 . . . an0n0
2
6664
3
7775
et1
et2
. . .
etn0
2
6664
3
7775 ¼ k
et1
et2
. . .
etn0
2
6664
3
7775: ð10Þ
Now, from Eq. (10), we can provide the following equations:
a11  et1 þ a12  et2 þ . . .þ a1n0  etn0 ¼ k  et1; ð11Þ
a21  et1 þ a22  et2 þ    þ a2n0  etn0 ¼ k  et2; ð12Þ
    et1 þ     et2 þ        þ     etn0 ¼ k     ; ð13Þ
an01  et1 þ an02  et2 þ    þ an0n0  etn0 ¼ k  etn0 ; ð14Þ
where k is known value that is already computed using Eq. (9).
Finally, from Eqs. (11)–(14), we can compute eti (i.e., the compo-
nent of the eigenvector Et) for each biomolecule (where
1 6 i 6 n0). The eigenvector centrality score of the vertex i (i.e.,
ECði;GÞ) can be defined as:
ECði;GÞ ¼ eti; ð15Þ
where, EvðiÞ denotes the component corresponding to the vertex i
of the eigenvector Ev, and G denotes the graph (or, network).
Notably, as we have drawn the TF-miRNA-gene undirected net-
work by considering only the undirected interactions between bio-
molecules (i.e., genes, TFs and miRNAs) rather than directed
interactions, thus the adjacency matrix denoted by A of the undi-
rected network is prepared as a symmetric matrix (see Eq. (7)).
Therefore, its eigenvectors are real.
For example, in Fig. 2, DC of vertex B and DC of vertex D are
same. But, EC of vertex D is greater than EC of vertex B as vertex
D is connected to two non-leaf vertices C and E, whereas vertex B
is connected to one leaf vertex A and one non-leaf vertex C. Thus,
D is more central (influential) than B.
In our experiment, the TFs, genes and miRNAs are then ranked
with respect to eigenvector centrality (i.e., EC). Thereafter, we have
considered each of the four gene-sets (viz., (DEdown \ DMhyper),
(DEup \ DMhypo), (DEup \ DMhyper) and (DEdown \ DMhypo)), separately
for biological validation through KEGG pathways and GENE
ONTOLOGY ENRICHMENT using the David database [54] that fol-
lows modified Fisher’s Exact test (modified as EASE score) [56].
Fig. 2. A small graph.
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For evaluating the effectiveness and superiority of our proposed
ranking method over the other existing methods, we have per-
formed hub gene and non-hub gene classifications on the genes
of DEM set into two class-labels, hub gene and non-hub gene using
the proposed ranking method (through eigenvector centrality
score of the genes in descending order) and other ranking methods
(through other centrality scores like betweenness centrality (BC),
degree centrality (DC), k-coreness centrality (KC), subgraph cen-
trality (SC), closeness centrality (CC), clustering coefficient-based
centrality (CCC) and weighted clustering coefficient-based central-
ity (WCCC) scores of the genes in descending order), individually
for the genes of DEM set of the multi-informative uterine leiomy-
oma Dataset.
For the purpose of hub gene and non-hub gene classification,
first of all, we have to know about the original class-labels of the
genes (viz., hub-gene class and non-hub-gene class). For original
hub gene selection, we apply a standard graph-theoretic approach
(i.e., ‘‘within-modulo z-score” of ‘‘Functional Cartography” method
[48]) on the genes. To do so, normalized z-score of the within-
modularity score (i.e., within-modulo z-score or shortly zwmodule)
[48] is computed for each gene of DEM. Zwmodule can be stated as
following.
zwmodulej ¼
lkj  lkmj
rlkmj
; ð16Þ
where lkðjÞ denotes the number of edges of node j to other nodes in
its module mj;rlkmj refers to standard deviation of lk in the module
mj, and lkmj denotes the mean of lk for all the nodes of the module
mj. The within-modulo z-score is such a measure which
demonstrates how well-connected node j is to other nodes in its
module.
The number of hub genes are much less than the number of
non-hub genes. Thus, the genes whose within-module degree
probability are less than 0.01, are considered as original hub genes.
Analogously, according to [48], the genes whose within-modulo
z-score are greater than equal to 2.5, are identified as original
hub genes of the network [48]; and remaining genes of DEM set
becomes original non-hub genes of the network.
After obtaining set of original hub genes and set of original non-
hub genes, we consider a certain quantity of top ranked genes (viz.,
top 15 genes, top 20 genes, top 25 genes, top 30 genes, top 35
genes and top 40 genes, individually in our experiment) having
higher values calculated from each centrality, are predicted as
hub genes, and rest of the genes of DEM set are predicted as
non-hub genes. Thereafter, different statistical terms of hub gene
and non-hub gene classification (i.e., average specificity, average
sensitivity, average accuracy and average F-measure) are com-
puted for each case in order to evaluate the appropriateness and
effectiveness of our proposed ranking method over the other meth-
ods in the network. The statistical terms are described in Table 1.2.2.4. Comparative study through pre-ranked gene set enrichment
analysis (pre-ranked GSEA)
The p-value can be stated as the probability under the assump-
tion of hypothesis (H0) of getting a result equal to or more extreme
than observed value. If the p-value is smaller, then the significance
level becomes higher as it shows that the hypothesis (H0) under
consideration might not sufficient or acceptable to demonstrate
the observation.
At first, we take all the genes of (DEdown \ DMhyper) type, and then
prepared a pre-ranked list of them using different centrality meth-
ods, individually. Thereafter, for comparing between the proposed
ranking method with the other ranking methods, we utilize pre-
ranked Gene set enrichment analysis (pre-ranked GSEA) [51] on
the pathway database (viz., c2:cp:kegg:v4:0:symbols:gmt of Molec-
ular Signatures Database (MSigDB)) as well as GO-term databases
(viz., c5:bp:v4:0:symbols:gmt; c5:cc:v4:0:symbols:gmt and
c5:mf :v4:0:symbols:gmt of Molecular Signatures Database
(MSigDB)) with providing the pre-ranked list of genes depending
on each centrality method. Here, the enrichment score (ES) [51]
of a KEGG pathway or GO-term (geneset) is defined as the maxi-
mum deviation from zero encountered in the random walk which
follows a weighted Kolmogorov–Smirnov-like statistic. Here, we
calculate a normalized enrichment score (NES) by normalizing
the ES for every KEGG pathway or GO-term (geneset). Using the
pre-ranked GSEA, we compute the statistical significance (i.e.,
nominal p-value) of the NES for each KEGG pathway or GO-term
(geneset) through an empirical phenotype-oriented permutation
test technique which considers the complex correlation of the gene
expression data. The nominal p-value cutoff (i.e., threshold of
significant-level) is set to 0.05 which is maximum cutoff. There-
after, the KEGG pathways or GO-terms of which nominal p-
values are less than the threshold (< 0:05), are selected as signifi-
cant KEGG pathways or GO-terms. Thereafter, average of the nom-
inal p-values of the significant KEGG pathways or GO-terms for
each ranking method is computed, and then compared with each
other. Similarly, we consider all the genes of (DEup \ DMhypo) type,
and then prepared another pre-ranked list of them using the differ-
ent centrality methods, individually, and perform the pre-ranked
GSEA, consecutively. We have already described earlier that lower
p-value denotes higher significance level. Now, as the average
nominal p-value of NES of the significant KEGG pathways or GO-
terms using the eigenvector centrality-based ranking method is
lowest among these of the other ranking methods in the pre-
ranked GSEA, thus the eigenvector centrality-based ranking
method provides better ranking than the other ranking methods.
Notably, in [55], similar comparative analysis among different
Gene Set Analysis Methods has been performed based on the
p-values of the pathways using the methods, where lower
p-value denotes better significance level.
Furthermore, it is noted that according to Abatangelo et al. [50],
the GSEA performs better than the standard enrichment analysis
using Fisher’s exact test.3. Results and discussion
In this section, we will describe the source of a real-life dataset
that is used in our experiments, as well as the experimental results
and discussion.
3.1. Dataset
In our experiment, we utilize uterine leiomyoma dataset (NCBI
Ref. id.: GSE31699) [13] having gene expression data of 48,803
genes and genome-wide DNA methylation data of 27,579 genes,
13072 of which are common to both. We use these 13072 genes
Table 1
Different statistical terms related to our comparative study (i.e., sensitivity, specificity, accuracy and F-measure).
Condition (originally)
#Hub_gene #Nonhub_gene
Predicted
#Hub_gene True positive (TP) False positive (FP) (Type I error) Positive predictive value (PPV) ¼ TPTPþFP
#Nonhub_gene False negative (FN) (Type II error) True negative (TN) Negative predictive value (NPV) ¼ TNFNþTN
Sensitivity (SN) ¼ TPTPþFN Specificity (SP) ¼ TNFPþTN Accuracy ¼ TPþTNTPþFPþTNþFN
F-measure ¼ 2PPVSNPPVþSN
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leiomyoma tumor (LM) samples and 16 common normal myome-
trial (MM) samples.3.2. Experimental results and discussion
For each dataset, pre-test filtering (i.e., removal of 30% genes
having lowest variance), zero-mean normalization, and application
of Limma statistical test are performed, consecutively. Let us
assume that set of non-differentially expressed genes and set of
non-differentially methylated genes are denoted by DEnon and
DMnon, respectively. Here, for the combined dataset, we identify
eight different types of gene-sets, viz., (a) (DEup \ DMnon) = 160,
(b) (DEup \ DMhyper) = 19, (c) (DEnon \ DMhyper) = 1920, (d) (DEdown\
DMhyper) = 76, (e) (DEdown \ DMnon) = 176, (f) (DEdown \ DMhypo) = 21,
(g) (DEnon \ DMhypo) = 2240, and (h) (DEup \ DMhypo) = 55 (see
Fig. 3). As our analysis concerns about both expression and
methylation levels, thus we choose only those genes that have both
expression and methylation values. Thus, we select only the gene-
sets denoted by (b), (d), (f) and (h) for our experiment. We have
accumulated a total of 171 genes (i.e., (19 + 76 + 21 + 55) genes)
by taking union of the selected gene-sets.
As stated in Section 2.2, a network, consisting of the genes, TFs
and miRNAs is built. As the whole network is very large, thus weFig. 3. Pie chart: containing (a) (DEup \ DMnon), (b) (DEup \ DMhyper) (i.e., the region
depicted by pink-color), (c) (DEnon \ DMhyper), (d) (DEdown \ DMhyper) (i.e., the region
depicted by green-color), (e) (DEdown \ DMnon), (f) (DEdown \ DMhypo) (i.e., the region
depicted by sky-color), (g) (DEnon \ DMhypo), and (h) (DEup \ DMhypo) (i.e., the region
depicted by red-color). Here, the (colorful) gene-sets denoted by (b), (d), (f) and (h)
are chosen for our experiment. Here, INTSEC denotes Intersection. (For interpretation
of the references to colour in this figure legend, the reader is referred to the web
version of this article.)provide this figure as a supplementary file entitled as ‘‘Supp_
Wholenetwork.tif”. In this network, all the vertices (viz.,
biomolecules) are arranged according to their ranking by the
values of EC. In the network, the vertices that have higher ranks,
are presented in the bottom portion of the network, and the
vertices that have lower ranks, are presented in the top portion
of the network. Here, circular and pink-colored vertices are TFs;
circular and orange-colored vertices are genes; triangular and
orange-colored vertices denote miRNAs. Top ten TFs, miRNAs and
genes are presented in larger size.
After calculating the eigenvector centrality measures from the
TF-miRNA-gene network, FOSL1, JUND, HIF1A, FOS, TP53, RELA,
CEBPB, ZFP36, SP1 and JUN are identified as top ten central TFs
whose EC values are 0.0234, 0.0180, 0.0165, 0.0162, 0.0158,
0.0157, 0.0153, 0.0097, 0.0087 and 0.0086, respectively (see
Table 2). Interestingly, DC of FOSL1 is 1, but for JUND, it is 2. Thus,
JUND would be more important if we consider only DC instead of
EC. But, according to our approach, FOSL1 is more significant
(important/central) than JUND as EC of FOSL1 is 0.0234 whereas
for EC of JUND is 0.0180. Similarly, JUND is more significant/central
than HIF1A. For the genes, PTGS2, MMP9, TACSTD2, SLC16A3,
ITGB4, HOXA5, FBLN2, HTATIP2, TNFSF10 and HOXA10 are found
as the top ten central genes of which EC values are 0.2340,
0.2157, 0.2138, 0.2137, 0.2131, 0.1953, 0.1949, 0.1946, 0.0646
and 0.0425, respectively (see Table 4). Here, HTATIP2 is more
central than TNFSF10 in spite of lower DC value of HTATIP2 than
this of the other. Similarly, APOE is more central than GRIA2. InTable 2
Top 25 central TFs with their degree centrality (DC), and eigenvector centrality (EC)
using our proposed approach.
TF DC EC
FOSL1 1 0.023353683
JUND 2 0.01795416
HIF1A 4 0.016531754
FOS 5 0.016189896
TP53 4 0.015804474
RELA 3 0.015670359
CEBPB 2 0.015318117
ZFP36 2 0.009689527
SP1 6 0.008718015
JUN 4 0.00864537
USF2 3 0.008508232
HOXA9 2 0.007901275
CREB1 1 0.007773591
ETV4 1 0.007773591
NFATC1 1 0.007773591
NFATC2 1 0.007773591
PPARA 1 0.007773591
SREBF1 1 0.007773591
SREBF2 1 0.007773591
USF1 1 0.007773591
IRF1 2 0.007171699
NFKB1 1 0.007163788
STAT3 1 0.007163788
EHF 1 0.007102281
ESRRB 1 0.007102281
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ITGB4, HOXA5 etc. have similar type inverse relationships between
the methylation and expression patterns (viz., DEdown \ DMhyper),
which are significant in biological point of view. Similarly,
HOXA10, APOE, GRIA2 etc. have also similar type inverse
relationships between the two patterns (viz., DEup \ DMhypo).
For validation, at first we have considered the set of 55 genes of
DEup \ DMhypo type, and then performed KEGG pathways and GENE
ONTOLOGY ENRICHMENT using the David Database [54]. For the
purpose of KEGG and GO ontology enrichment analysis, we have
set 0.05 as p-value threshold for each pathway/GO-term; i.e., if a
pathway/GO-term has p-value less than 0.05, then the pathway/
GO-term becomes p-value significant. We have considered only
the p-value significant pathways/GO-terms in resulting list. In
the case of the set of 55 genes of DEup \ DMhypo type, we have iden-
tified 2 significant pathways, 31 significant GO:BPs, 7 significant
GO:CCs, and 2 significant GO:MFs. Similarly, we have identified
significant KEGG pathways and gene-ontologies for the set of 76
genes of DEdown \ DMhyper type. Here, we have obtained 1 significant
pathway, 34 significant GO:BPs, 9 significant GO:CCs, and 7 signif-
icant GO:MFs. Besides that, there are 1 significant GO:BPs, and 2
significant GO:CCs found for the set of 19 genes of DEup \ DMhyper
type. Finally, we have got 38 significant GO:BPs, 4 significant GO:
CCs, and 1 significant GO:MFs for the set of 21 genes of
DEdown \ DMhypo type. For example, PTGS2 (in the type of
DEdown \ DMhyper) is involved in 20 GO:BPs, and 4 GO:CCs. For
details, see ‘‘Supp1_pathwayGO_uphypo.xls”, ‘‘Supp2_pathwayGO_
downhyper.xls”, ‘‘Supp3_pathwayGO_uphyper.xls”, and ‘‘Supp4_
pathwayGO_downhypo.xls” files for the DEup \ DMhypo type,
DEdown \ DMhyper type, DEup \ DMhyper type, and DEdown \ DMhypo type,
respectively. Similarly, miR-155, miR-155⁄, miR-146a, miR-146a⁄,
miR-10a, miR-10a⁄, miR-150⁄, miR-144, miR-144⁄ and miR-17
are identified as top ten central miRNAs whose EC values are
0.0828, 0.0828, 0.0809, 0.0809, 0.0803, 0.0803, 0.0802, 0.0799,
0.0799, 0.0799, respectively (see Table 3). In this case, miR-144
and miR-144⁄ are both more central than both of miR-17 and
miR-17⁄ in spite of lower ODC values of the miR-144 and miR-
144⁄ than these of the others. However, the top 25 central TFs,Table 3
Top 25 central miRNAs with their degree centrality (DC), and eigenvector centrality
(EC) using our proposed approach.
miRNA DC EC
miR-155 14 0.082751299
miR-155⁄ 14 0.082751299
miR-146a 7 0.080881914
miR-146a⁄ 7 0.080881914
miR-10a 3 0.080273456
miR-10a⁄ 3 0.080273456
miR-150⁄ 3 0.080219104
miR-144 2 0.079990769
miR-144⁄ 2 0.079990769
miR-17 6 0.079902701
miR-17⁄ 6 0.079902701
miR-146b-3p 3 0.079805947
miR-146b-5p 3 0.079805947
miR-181a 4 0.079751072
miR-181a⁄ 1 0.079751072
miR-181a-2⁄ 1 0.079751072
miR-15b 3 0.079565867
miR-15b⁄ 3 0.079565867
miR-150 2 0.079384157
miR-125b 5 0.079269153
miR-125b-1⁄ 1 0.079269153
miR-125b-2⁄ 1 0.079269153
miR-143 3 0.07921072
miR-143⁄ 3 0.07921072
miR-145 3 0.07921072genes and miRNAs in our network are presented with the central-
ity measures in Tables 2, 4 and 3, respectively.
In the network diagram, after the ranking using EC, for recogniz-
ing TFs, miRNAs and genes from the biomolecules in the network,
we have considered their indegree centrality (IDC) and outdegree
(ODC) centrality. In the network, non-looped TFs or miRNAs are
those which have both ODC– 0 and IDC = 0. The genes have both
IDC– 0 and ODC = 0.
According to our network, the transcription factor FOSL1 regu-
lates only one gene MMP9 whose EC value is very high (i.e.,
0.21569). MMP9 is also regulated by another 54 TFs/miRNAs
(viz., JUND, TP53, RELA, SP1 etc. as the top central TFs, and miR-
155, miR-155⁄, miR-17 etc. as the top central miRNAs). Hence,
FOSL1 becomes top central TF due to its involvement with MMP9
which is also highly central gene. The top central gene PTGS2 is tar-
geted by miR-146a, miR-146a⁄, miR-155, miR-155⁄, miR-10b, miR-
10b⁄, etc. and is regulated by the top central TFs like TP53, FOS,
HIF1A, CE-BPB, RELA, JUN etc. Similarly, MMP9 is targeted by
miR-155, miR-155⁄, miR-17, miR-17⁄, miR-146b-5p, miR-181a
etc. and is regulated by the top central TFs like FOSL1, JUND,
TP53, RELA, SP1 etc. The top central miR-155 and miR-155⁄ both
target MMP9, TACSTD2, SLC16A3, TNFSF10, HOXA10, ITGB4 etc.
top central genes. Similarly, miR-146a and miR-146a⁄ both target
PTGS2, APOE, SOCS3 etc.
Notably, we also represent a sub-network (Fig. 4) of the previ-
ous network. The sub-network contains only the first/nearest
neighbors (TFs and miRNAs) of top 5 enriched genes (PTGS2,
MMP9, TACSTD2, SLC16A3, and ITGB4). This sub-network contains
the first/nearest neighbors (TFs and/or miRNAs) of those enriched
genes. Here, circular and orange-colored vertices are genes, circular
and pink-colored vertices are TFs, triangular and orange-colored
vertices denote miRNAs. Target of some vertex to another is
denoted by ‘a’ sign in the sub-network.
Moreover, we have obtained some top novel potential gene-
markers (viz., PTGS2 and TACSTD2) for the uterine leiomyomas
(LMS) tumor type using the eigenvector centrality method inte-
grating gene expression and methylation data. These specify thatTable 4
Top 25 central genes with their degree centrality (DC), and eigenvector centrality (EC)
using our proposed approach.
Gene DC EC Status
PTGS2 67 0.234045069 DEdown \ DMhyper
MMP9 55 0.21568528 DEup \ DMhyper
TACSTD2 20 0.213833463 DEdown \ DMhyper
SLC16A3 18 0.213674862 DEup \ DMhyper
ITGB4 17 0.213125775 DEdown \ DMhyper
HOXA5 16 0.195345866 DEdown \ DMhyper
FBLN2 5 0.19485029 DEdown \ DMhyper
HTATIP2 4 0.194635336 DEdown \ DMhyper
TNFSF10 41 0.064581107 DEdown \ DMhyper
HOXA10 39 0.042543464 DEup \ DMhypo
APOE 15 0.034032398 DEup \ DMhypo
GRIA2 23 0.032226034 DEup \ DMhypo
SOCS3 33 0.030639618 DEdown \ DMhyper
CCL5 25 0.028467833 DEdown \ DMhypo
PECAM1 20 0.025138351 DEdown \ DMhyper
SERPINE1 21 0.021545568 DEdown \ DMhyper
SOX17 11 0.015768702 DEdown \ DMhyper
CRIM1 12 0.014789059 DEdown \ DMhyper
CBX7 14 0.012215291 DEdown \ DMhyper
DUSP1 7 0.011039935 DEdown \ DMhyper
EDNRB 6 0.010706471 DEdown \ DMhyper
BEX1 6 0.010546914 DEup \ DMhypo
BCAN 5 0.010533102 DEup \ DMhypo
PRKD1 6 0.008629279 DEup \ DMhyper
DCN 19 0.00848684 DEdown \ DMhypo
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simultaneous downregulation and hypermethylation of PTGS2
gene, and (ii) simultaneous downregulation and hypermethylation
of TACSTD2 gene. These signatures may have potential medicinal
value.
We have also conducted a comparative analysis between our
proposed methodology (i.e., ranking TFs/genes using EC) and the
basic approach of ranking TFs/genes using DC values. For this pur-
pose, we have chosen top 25 central TFs from each of the two cases
and checked their number of tumor-related KEGG pathways andFig. 4. A TF-miRNA regulatory network for only top 5 enriched genes (gene ontologies using David database. Notably, in order to choose
the number of top central TFs that will be used for the comparative
study, firstly we have ordered the EC values of the TFs in descend-
ing order, and then plotted these in a single graph. First quick fall
from the top EC values in the graph is identified. As there are only 6
top TFs that belong to the first fall from the top, thus we consider
2nd quick fall, and the top TFs belonging to the 2nd quick fall from
the top (viz., approximately 25 TFs) are identified (see Fig. 5). Sim-
ilarly, we have chosen the top central 25 genes for the comparative
study. In our proposed approach, we have obtained 7 significantviz., PTGS2, MMP9, TACSTD2, SLC16A3, and ITGB4) of the dataset.
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Adipocytokine, Wnt signaling pathways etc.), 146 GO:BPs, 14 GO:
CCs and 21 GO:MFs in which the TFs are involved; whereas theseFig. 5. The plot of EC values of the TFs in descending order with respect to the
number of top central TFs.
Table 5
Comparison of average accuracies and average F-measures of hub gene and non-
other ranking methods for the mentioned dataset.
Ranking Average Average
method sensitivity [%] specificity [%
(s.d.) (s.d.)
EC 95.238 (11.66) 72.588 (11.63
BC 92.882 (9.87) 72.464 (12.85
DC 92.857 (11.95) 72.370 (11.41
KC 92.855 (7.83) 72.370 (11.68
SC 85.712 (9.03) 71.710 (11.61
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Fig. 6. Comparison of (a) average accuracies and (b) average F-measures, of hub ge
Eigenvector centrality measure) and other ranking methods for the mentioned datas
centrality, KC = k-coreness centrality and SC = subgraph centrality.numbers are only 5, 86, 13 and 17 respectively, for ranking with
only DC values. Similarly, we have identified 56 GO:BPs and 6
GO:CCs in which the genes exist for EC approach. But, for DC
approach, these numbers are 28 and 5, respectively.3.3. Comparative results through classification of network hub genes
The comparative results of hub gene and non-hub gene classifi-
cation between the proposed method and other ranking methods
(i.e., BC, DC, KC and SC) for the genes of DEM set of the multi-
informative dataset are represented in Table 5, Fig. 6(a) and (b).
According to Table 5, the proposed ranking method provides
higher average accuracy (viz., 74.498%) and higher average
F-measure (0.4033) in hub gene and non-hub gene classification
than the other ranking methods. See Fig. 6 (a) and (b) for better
pictorial representation.
Notably, closeness centrality (CC), clustering coefficient-based
centrality (CCC) and weighted clustering coefficient-based central-
ity (WCCC) measures are not utilized in the comparative study as
these measures are not appropriate for the corresponding network.
For example, centrality values of all genes become zero for CCmea-
sure. For each of CCC and WCCC measures, centrality value of the
maximum number of genes becomes either 1 or 0; i.e., there are
very few fractional centrality values. Therefore, top genes are not
differentiable through these centrality measures. Therefore, wehub gene classification between proposed ranking method (through EC) and
Average Average
] accuracy [%] F-measure
(s.d.) (s.d.)
) 74.498 (10.09) 0.4033 (0.082)
) 74.146 (9.97) 0.3983 (0.097)
) 74.097 (9.66) 0.3910 (0.065)
) 74.097 (10.13) 0.3957 (0.088)
) 72.892 (10.01) 0.3636 (0.073)
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(b)
ne and non-hub gene classification between proposed ranking method (through
et. Notably, EC = eigenvector centrality, DC = degree centrality, BC = betweenness
Table 6
Comparison of average nominal p-values of normalized enrichment scores (NES) of significant KEGG pathways as well as GO-terms among different ranking
methods (i.e., through EC, DC, BC, KC, SC, individually) in our method with the other ranking methods using pre-ranked GSEA for DEdown \ DMhyper geneset.
Average p-value (s.d.)
KEGG pathway GO:BP GO:CC GO:MF
EC 0.0158 (0.0153) 0.0212 (0.0125) 0.0168 (0.0216) 0.0139 (0.0158)
DC 0.0211 (0.0144) 0.0244 (0.0116) 0.0205 (0.0164) 0.0141 (0.0157)
BC 0.0163 (0.0134) 0.0214 (0.0115) 0.0171 (0.0168) 0.0189 (0.0140)
KC 0.0214 (0.0157) 0.0214 (0.0126) 0.0175 (0.0171) 0.0173 (0.0183)
SC 0.0227 (0.0162) 0.0250 (0.0139) 0.0293 (0.0194) 0.0166 (0.0179)
Table 7
Comparison of average nominal p-values of normalized enrichment scores (NES) of significant KEGG pathways as well as GO-terms among different ranking
methods (i.e., through EC, DC, BC, KC, SC, individually) in our method with the other ranking methods using pre-ranked GSEA for DEup \ DMhypo geneset.
Average p-value (s.d.)
KEGG pathway GO:BP GO:CC GO:MF
EC 0.0256 (0.0164) 0.0218 (0.0163) 0.0133 (0.0228) 0.0205 (0.0175)
DC 0.0271 (0.0155) 0.0232 (0.0169) 0.0139 (0.0201) 0.0230 (0.0184)
BC 0.0296 (0.0145) 0.0222 (0.0182) 0.0141 (0.0176) 0.0225 (0.0185)
KC 0.0259 (0.0159) 0.0258 (0.0176) 0.0190 (0.0201) 0.0216 (0.0164)
SC 0.0257 (0.0145) 0.0236 (0.0170) 0.0137 (0.0189) 0.0241 (0.0169)
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analysis.3.4. Comparative results through pre-ranked GSEA
Using the pre-ranked GSEA analysis, we compute and then com-
pare the average nominal p-values of normalized enrichment
scores (NES) [51] of significant KEGG pathways as well as GO-
terms for each ranking method (through EC, DC, BC, KC, SC, individ-
ually) for DEdown \ DMhyper geneset (in Table 6) and DEup \ DMhypo
geneset (in Table 7), individually whereas the nominal p-value cut-
off (i.e., threshold of significant-level) is set to 0.05. According to
Table 6, the proposed ranking method through EC provides lowest
average nominal p-values for all cases (e.g., KEGG pathways, GO:
BPs, GO:CCs, GO:MFs) for DEdown \ DMhyper geneset. Similarly,
according to Table 7, the proposed ranking method through EC
yields lowest average nominal p-values for all cases (e.g., KEGG
pathways, GO:BPs, GO:CCs, GO:MFs) for DEup \ DMhypo geneset.
Therefore, these lowest average nominal p-values of NES for all
the cases (e.g., KEGG pathways, GO:BPs, GO:CCs, GO:MFs) in our
method signify better ranking than the other ranking methods.
For the case of pre-ranked GSEA using eigenvector centrality
based ranking by considering all the genes of DEup \ DMhypo type,
we have identified many p-value significant KEGG pathways/
GO-terms. Among them, cytokine-cytokine receptor interaction
pathway [59,60] (nominal p-value = 0.0227) is well-known uterine
leiomyoma related significant pathway. Besides that, GO-BPs of
extracellular structure organization and Biogenesis [64,65] (nomi-
nal p-value = 0.043), and growth factor beta receptor [66,67] (nom-
inal p-value = 0.043) are well-known uterine leiomyoma related
significant GO-BPs. The tumor related significant GO-CCs are GO-
CCs of extracellular matrix [64,65] (nominal p-value = 0.0017),
and extracellular region [64,65,68,69]. The tumor related
significant GO-MF is GO-MF of cytokine activity [59,60] (nominal
p-value = 0.0017). Similarly, in case of pre-ranked GSEA using
eigenvector centrality based ranking by considering all the genes
of DEdown \ DMhyper type, we have obtained many p-value
significant KEGG-pathways/GO-terms. Among them, p53 signaling
pathway [61,62] (nominal p-value = 0.0476) is well-known
uterine leiomyoma related pathway. The tumor related significant
GO:BPs are GO-BPs of cell–cell adhesion [69–71] (nominalp-value = 0.0144), and Jak/Stat cascade (nominal p-value = 0.0302)
[63]. Notably, the pathways/GOs which are enriched both in up-
regulated and down-regulated genes, are not considered here as
important significant pathways/GOs for the disease.
4. Conclusions
In this article, we have presented a new methodology in order
to rank biomolecules involved in uterine tumor by utilizing statis-
tical and centrality based techniques for a combined data having
both expression and methylation data. Genes which are both dif-
ferentially expressed and differentially methylated, are identified
using Limma test. Thereafter, transcription factors (TFs) which
have impact on these genes regulation, are identified from TRANS-
FAC professional database (release 2011.2) and ITFP website. Sub-
sequently, miRNAs that targets these genes, are identified using
miRWalk database. A network, containing the genes, the transcrip-
tion factors (TFs) and the microRNAs (miRNAs), is then developed.
The TFs, miRNAs and genes are then ranked based on eigenvector
centrality. However, in order to evaluate the effectiveness of the
eigenvector centrality-based ranking method over the other rank-
ing methods for the integrated dataset, we perform hub gene and
non-hub gene classifications using the proposed method and the
other methods, individually. Furthermore, we utilize pre-ranked
Gene set enrichment analysis (pre-ranked GSEA) software on the
pathway database as well as GO-term databases of Molecular Sig-
natures Database (MSigDB) with providing a pre-ranked list of
genes prepared by different centrality values of them in order to
compare centrality methods. Finally, we have identified some top
novel potential genemarkers (viz., PTGS2 and TACSTD2) for the
uterine leiomyomas (LMS) tumor using the proposed method for
the integrated dataset having gene expression and methylation
data. These specify that some possible novel signatures for the
uterine leiomyomas are (i) simultaneous downregulation and
hypermethylation of PTGS2 gene, and (ii) simultaneous downregu-
lation and hypermethylation of TACSTD2 gene. These signatures
may have potential clinical value.
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